An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2019
At a glance
- Drugs Volasertib (Primary) ; Itraconazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Jun 2019 Planned End Date changed from 15 Apr 2019 to 15 Sep 2019.
- 31 Oct 2018 Planned End Date changed from 15 Oct 2018 to 15 Apr 2019.
- 01 Jun 2018 Planned End Date changed from 15 Jun 2018 to 15 Oct 2018.